Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.

Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.

<h4>Background and aims</h4>Alcoholic steatohepatitis (ASH)-the inflammation of fatty liver-is caused by chronic alcohol consumption and represents one of the leading chronic liver diseases in Western Countries. ASH can lead to organ dysfunction or progress to hepatocellular carcinoma (H...

Full description

Bibliographic Details
Main Authors: Torsten Diesinger, Vyacheslav Buko, Alfred Lautwein, Radovan Dvorsky, Elena Belonovskaya, Oksana Lukivskaya, Elena Naruta, Siarhei Kirko, Viktor Andreev, Dominik Buckert, Sebastian Bergler, Christian Renz, Edith Schneider, Florian Kuchenbauer, Mukesh Kumar, Cagatay Günes, Berthold Büchele, Thomas Simmet, Dieter Müller-Enoch, Thomas Wirth, Thomas Haehner
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0235990

Internet

https://doi.org/10.1371/journal.pone.0235990

Similar Items